NEW DELHI – India is very well placed to tap into the biosimilars opportunities expected in the next 15 years, with its domestic market poised to grow to $40 billion by 2030, against a backdrop of an expected $240 billion growth in the global market, according to a newly released white paper on India’s potential in the sector. Read More
LONDON – Crescendo Biologics Ltd. has landed the first major partner for its Humabody pared back antibody constructs, agreeing to an oncology collaboration worth up to $790 million with Osaka, Japan-based Takeda Pharmaceuticals Ltd. Read More
PERTH, Australia – A venture capital fund has emerged in Australia that allows new migrants to invest in early stage biomedical companies in the country. Read More
TOKYO – Japan’s Daiichi Sankyo Co. Ltd. is making progress in the oncology field, a key sector for social well-being as the global population grows older. Read More
HONG KONG – Looking to leverage the “huge opportunity” in the ever-promising markets in Asia-Pacific, Mundipharma Pharmaceutical Co. Ltd. will launch Betadine, its first consumer health product in China, over the coming quarter. Read More
Continuing a flurry of dealmaking that has spanned both the generic and branded drug markets, Teva Pharmaceutical Industries Ltd. inked its latest deal, a North American alliance with Korean firm Celltrion Inc. aimed at expanding its role in the growing biosimilars space. Read More
HONG KONG – A University of Hong Kong (HKU) phase II trial has shown that a drug derived from an herb used in traditional Chinese medicine to treat acute myeloid leukemia (AML) has helped patients with an aggressive treatment-refractory form of AML to achieve remission. Read More
Samsung Bioepis Co. Ltd., of Incheon, Korea, said its marketing authorization application for SB3, a biosimilar candidate referencing Herceptin (trastuzumab, Roche Holding AG), a monoclonal antibody indicated for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer, has been accepted for review by the EMA. Read More
